Led · Series A · Dec 2025

Bioxodes is a clinical-stage biopharmaceutical company focused on novel therapies that address both thrombotic and inflammatory diseases. Its lead candidate, BIOX-101, delivers anticoagulant effects without increasing bleeding risk while simultaneously exerting anti-inflammatory action through modulation of neutrophils. This dual mechanism is expected to improve survival rates and recovery outcomes for patients suffering intracerebral hemorrhage (ICH) and related indications. The company holds a portfolio of granted and pending patents protecting BIOX-101 worldwide. Proceeds from recent financings are earmarked for expanding operations and advancing clinical development of the asset. To date, Bioxodes has secured €17.5 million in Series A funding, underscoring investor confidence in its therapeutic approach. No commercial revenue or user metrics have been disclosed at this stage of development.

Participated · Series A · Mar 2025

Augustine Therapeutics develops selective inhibitors of the cytosolic histone deacetylase 6 (HDAC6) enzyme for chronic indications. Its lead program, AGT-100216, is described as the first selective HDAC6 inhibitor designed for long-term treatment of Charcot-Marie-Tooth (CMT) disease. The company highlights a non-hydroxamate, non-hydrazide chemotype intended to provide selectivity and avoid limitations of other chemotypes, and says the approach is built for chronic diseases. Augustine plans to use newly raised capital to advance AGT-100216 through a Phase I/II proof-of-concept clinical trial in CMT. The company targets neuromuscular, neurodegenerative and cardio-metabolic diseases with this selective HDAC6 approach. Augustine is led by CEO Gerhard Koenig and was founded on research by Prof. Ludo Van Den Bosch at VIB-KU Leuven in Belgium. The recent financing strengthens its balance sheet to support clinical development. Augustine Therapeutics is developing novel, potent, subtype-selective small-molecule inhibitors of the cytosolic HDAC6 enzyme targeting neurodegenerative and cardiometabolic diseases. Its lead candidate, AGT100216, is a peripherally restricted selective HDAC6 inhibitor that has shown impressive preclinical efficacy in Charcot‑Marie‑Tooth (CMT) studies and peripheral neuropathies induced by chemotherapy (CIPN). The company’s chemistry is distinct from first-generation hydroxamate-based HDAC6 inhibitors and is designed to safely and selectively reverse pathophysiological changes associated with neuromuscular and neurodegenerative diseases. Augustine plans to advance AGT100216 into a Phase 1/2 first-in-human clinical trial in 2025 and to develop next-generation candidates with peripheral-restricted or brain-penetrant properties. Proceeds from the financing will also support expansion of the executive and R&D teams. Augustine was founded in 2019 as a VIB-KU Leuven spin-off and is based in Leuven, Belgium. Augustine Therapeutics is focused on the discovery and development of innovative therapeutics for Charcot‑Marie‑Tooth disease (CMT) and other neuromuscular disorders. The company is rooted in research from the VIB–KU Leuven labs of Ludo Van Den Bosch and collaborations between the labs of Joris de Wit and Bart De Strooper, which uncovered biological pathways and therapeutic targets in peripheral neuropathies. VIB Discovery Sciences is leading the preclinical development of Augustine’s new therapeutics and will apply industry-trained drug discovery expertise to the early pipeline. Augustine completed a €4.2 million seed financing to support target validation and early-stage development. Day-to-day interim management is being handled by Ward Capoen (V-Bio Ventures) and Jérôme Van Biervliet (VIB) while the company seeks a dedicated management team. The company aims to advance validated targets toward novel treatments that address the limited therapeutic options for CMT patients.

Participated · Series A · Sep 2023

AbolerIS Pharma is a Belgian biopharmaceutical company focused on immunotherapies for autoimmune and inflammatory diseases. Its lead program is a monoclonal antibody that targets the novel receptor CD45RC with the goal of restoring immune tolerance. The company aims for durable remissions and therapies with fewer side effects compared with current immunosuppressive options. Cofounders Dr. Ignacio Anegon and Dr. Carole Guillonneau and a team of experienced immunology scientists lead the research. The financing announced will be used to accelerate the clinical development of the antibody and advance it toward becoming a potential new treatment standard for conditions such as rheumatoid arthritis.

Led · Series A · Jun 2023

Santero is a Charleroi, Belgium–based spin-off of the Université libre de Bruxelles focused on developing antibiotics against multi-drug resistant infections. Founded by Cedric Govaerts and Abel Garcia-Pino, the company is advancing first-in-class inhibitors aimed at treating infections that current recent antibiotic classes do not address. The founders highlight the gap that since 2000 only five new antibiotic classes have been marketed and none target the Gram-negative bacteria responsible for many AMR infections. Santero intends to use proceeds from its recent financing to further develop its lead inhibitor programs toward clinical advancement. The company says its work will add new treatment options to improve patient survival and recovery from multi-resistant bacterial infections. It raised funding in 2023 to support these development plans.

Led · Series A · Jan 2023

DeuterOncology is developing less invasive therapeutic approaches for lung cancer. The company has reported initial encouraging results from early clinical testing. It has raised €5 million to continue and expand those clinical trials to a larger panel of patients. DeuterOncology plans to use the new funding to confirm efficacy and safety in broader studies. The articles do not provide revenue, user metrics, founding year, or detailed financial history.